Drug development

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Orphan drugs #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry

New Tools Increase Accessibility to High Content Screening Assays

New Tools Increase Accessibility to High Content Screening Assays By Dr John Comley There have been major improvements in the instrument offerings and tools that enable high content screening (HCS) over the past decade. In this review we examine the status of high content screening assays today; the motivation to… Read More

#Archive

#Assay development optimisation & technology #Biochemistry #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Oncology #Pharmacology #Regulatory #RNA #Screening #Stem cells #System biology #Therapeutics #Urinary

Ubiquitination, E3 Ligases and Drug Discovery – Novel technologies for a challenging pathway

Ubiquitination, E3 Ligases and Drug Discovery - Novel technologies for a challenging pathway By Dr Neil Wilkie and Dr Steve Davies Does ubiquitin drug discovery provide the opportunity for a new class of therapeutic agents? This article argues that new technological advances are removing many of the barriers that have… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Orphan drugs #PCR #Pharmacology #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Stem Cells: Cell-Based Assays and the World of Small Molecules

Stem Cells: Cell-Based Assays and the World of Small Molecules By Dr Christina N. Ramirez, Dr Dana C. Duré and Dr Hakim Djaballah Stem cells remain a hot topic in academia and industry alike, and with the potential to cause a paradigm shift where many believe in their ability to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Innovate While Derisking Drug Development: Yes We Can!

Innovate While Derisking Drug Development: Yes We Can! Taher Abbasi, Pradeep Fernandes, Dr Shireen Vali and Professor Gurkirpal Singh The outlook for the drug industry continues to remain bleak in context of productivity and success rates. In spite of ongoing increase in R&D expenses and technology revolutions in the genomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Business #Clinical specialities #Clinical trials #Drug development #Enabling technologies #High Content Screening #Imaging #Mass spectrometry / NMR #Oncology #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #System biology #Translational #Translational chemistry

In Vivo Imaging In Drug Development: Gamma Scintigraphy

In Vivo Imaging In Drug Development: Gamma Scintigraphy By Dr Alyson Connor Gamma scintigraphy is a non-invasive technique with applications in the development of drug products and the assessment of pharmacodynamic effects in humans. It enables the assessment of critical performance parameters that in vitro techniques attempt, but often fail,… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Molecular medicine #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

The Application of iPS Cells and Differentiated Neuronal Cells To Advance Drug Discovery

By Dr Jeffrey Dage and Dr Kalpana Merchant While the jury is still out in terms of iPS cell technology and its ability to deliver a regenerative therapy or, indeed, contribute to the development of a clinical molecule, this paper argues that the progress by which this technology has been… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biobanking #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Patent Law #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation.

The Information Symphony: Data orchestration for a changing industry managing data on a platform for innovation. By Chris Molloy A leading ballet conductor (1) recently told me of courses which he runs for senior business leaders. He allows them to conduct an orchestra: first, very strictly, with close direction applied… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Molecular medicine #Oncology #PCR #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Toxicology #Translational #Translational chemistry #Urinary

Pathway Analysis – Understanding the bridge between environmental cues and cellular response

Pathway Analysis - Understanding the bridge between environmental cues and cellular response By Dr John Comley Understanding the function of a protein in the context of normal and abnormal cellular processes requires a comprehensive knowledge not only of its regulation but also of its role in signalling and metabolic networks… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #Imaging #Immunology #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology

Current and Emerging Trends In Immunogenicity Research

Current and Emerging Trends In Immunogenicity Research In November 2011 Drug Discovery World hosted a collegial style roundtable discussion on the present and emerging developments in this fundamental area of drug discovery and development. The participants are drawn from the biopharmaceutical, biotechnology and vendor community. Although somewhat sketchy in places… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Business #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Immunology #Lead discovery #Pharmacology #Preclinical #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

From Outsourced To Open: The continuing evolution of the drug discovery business model

From Outsourced To Open: The continuing evolution of the drug discovery business model Dr Mary Canady One doesn't have to look far to find that the large pharmaceutical business model has many market forces working against it, such as patent expirations, dwindling pipelines, and reduced R&D productivity. However, these factors… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Biomarkers #Business #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #High Content Screening #Imaging #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Pathology #Regenerative Medicine #Regulatory #RNA #Stem cells #Translational #Translational chemistry

Ontario as a Life Sciences Powerhouse

Ontario as a Life Sciences Powerhouse By Michael Stewart Around the world, competition between life sciences companies is fierce. And so is the competition between jurisdictions wanting to attract the good paying jobs, innovative spirit and R&D that comes along with this important economic sector. Different jurisdictions, including the UK,… Read More

#Archive

#Academic #Biomarkers #Business #Cell culture #Cell therapy #Drug development #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Patent Law #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

Stem Cell Banks: Investing in the promise of cancer stem cell science

Share Share Tweet Email Stem Cell Banks: Investing in the promise of cancer stem cell science Stem Cell Banks: Investing in the promise of cancer stem cell science By Madeline Page and Rosario Isasi The national and international demand for stem cell lines of varying origins (eg human embryonic, induced… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell culture #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #Pharmacology #Preclinical #RNA

Simultaneous Visualisation of Attrition and Timelines: Funnel Diagrams.

Simultaneous Visualisation of Attrition and Timelines: Funnel Diagrams. By Dr Linda Hirons, Dr Craig Johnstone and Colin Sambrook-Smith In drug discovery both attrition and timelines are important factors to consider when applying process improvement to lead optimisation. In our attempts to improve the visualisation of both of these factors simultaneously,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Enabling technologies #Flow Cytometry #Genetics #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #PCR #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation

Small Scale Benchtop Automation: Broadening the adoption of lab automation

Small Scale Benchtop Automation: Broadening the adoption of lab automation By Dr John Comley Driven by the need to enable technically challenging or repetitive processes, many labs in drug discovery that were not previously adopters of laboratory automation are being increasingly drawn to the potential of simple small-scale benchtop automation. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #RNA #Screening

Exploring the horizons of small molecule drug discovery

Exploring the horizons of small molecule drug discovery the evolution and application of the ideal fragment library By Dr David Myszka and Dr Jane Paul With the pharmaceutical industry facing unprecedented challenges in small molecule drug discovery, this paper argues that, with the correct design of the fragment library, Fragment-Based… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation

The Apocalyptic Horsemen of Drug Discovery and Development

The Apocalyptic Horsemen of Drug Discovery and Development By Dr Gary J. Keil The pharmaceutical industry should consider an evolutionary disease management approach based on homeostasis, irreversibility, biological alinearity, pseudo-N-of-1 health and disease states and narrative medicine best practices in order to help secure a successful drug development future. The… Read More

#Archive